TG Therapeutics Is Poised For Upside, Says Roth Capital Analyst
In a research note released today, Roth Capital reiterated coverage on TG Therapeutics, Inc. (TGTX) with a Buy rating and a price target of $15.00.
Roth’s analyst Dr. Joseph Pantginis expects important visibility out of TG this weekend at EHA. Phase II combination data will be presented from the TG-1101 / Imbruvica study in B-cell malignancies. According to the analyst, this study is the “match made in heaven” combination and he believes the data will not disappoint by delivering strong response rates. “We believe the stock is poised for upside at the start of next week”, said Dr. Pantginis.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, Dr. Joseph Pantginis, who covers TGTX, has a one-year average return of 1.5% and a 44% success rate.